AMD progresses through several stages, usually starting with dry AMD, which is the more common form of the condition. It advances to geographic atrophy (GA) in some cases. Both conditions damage ...

PST-611 is a first in class non-viral vectorized therapy for the treatment of dry age-related macular degeneration (AMD)/geographic atrophy (GA), expressing human transferrin, a highly potent iron ...

Shares in US biotech Iveric Bio have shot up after the company said its lead drug Zimura had slowed eyesight deterioration in patients with the dry form of age-related macular degeneration (AMD ...

The pharmaceutical industry is increasingly focused on developing pathway-based therapies for dry AMD, with promising treatments like ALK-001 and LBS-008 in trials, though a combination approach ...

PST-611 is a first-in-class non-viral vectorized therapy for the treatment of dry AMD/GA, expressing human transferrin, a highly potent iron regulator, to restore normal iron homeostasis.

PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD PulseSight Therapeutics S.A.S Thu, Feb 13, 2025, 3:00 AM 3 min read ...